We are Fulfilling Unmet Needs in Pulmonary Medicine. Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease. Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following: • Continued development of proprietary respiratory disease therapies • Pursue regulatory pathways that reduce the time, costs and risks associated with product development • Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing • Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States • Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise
Company Growth (employees)
Type
Public
HQ
Hayward, US
Size (employees)
16 (est)
Aradigm is headquartered in Hayward, US

Key People at Aradigm

Igor Gonda

Igor Gonda

President & Chief Executive Officer
Nancy Pecota

Nancy Pecota

Chief Financial Officer

Aradigm Office Locations

Aradigm has an office in Hayward
Hayward, US (HQ)
3929 Point Eden Way

Aradigm Metrics

Aradigm Financial Metrics

Revenue (2015)

$23.4 m

Revenue growth (2014-15), %

(30%)

Net income (2015)

($17.2 m)

Market capitalization (28-Apr-2017)

$17.3 m

Closing share price (28-Apr-2017)

$1.2

Cash (31-Dec-2015)

$31.5 m
Aradigm's current market capitalization is $17.3 m.
Aradigm's revenue was reported to be $23.4 m in FY, 2015 which is a 30% decrease from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

$9.7 m$33.6 m$23.4 m

Revenue growth, %

245%(30%)

Operating expense total

$29.6 m$37.4 m$40.6 m

EBIT

($19.9 m)($3.9 m)($17.2 m)

EBIT margin, %

(205%)(11%)(73%)

Interest expense

$1.6 m$288 k$288 k

Interest income

$6 k$17 k$29 k

Net Income

($21.6 m)$4.7 m($17.2 m)
FY, 2013FY, 2014FY, 2015

Cash

$48.1 m$48 m$31.5 m

Accounts Receivable

Inventories

Current Assets

$49.7 m$50.5 m$35.2 m

PP&E

$400 k$502 k$299 k

Total Assets

$50.4 m$54 m$35.6 m

Accounts Payable

$619 k$2.7 m$1.8 m

Current Liabilities

$7.3 m$6.8 m$7.5 m

Retained Earnings

($392.9 m)($388.3 m)($405.5 m)

Total Equity

$33.7 m$39.1 m$23.1 m

Financial Leverage

1.5 x1.4 x1.5 x
FY, 2013FY, 2014FY, 2015

Net Income

($21.6 m)$4.7 m($17.2 m)

Depreciation and Amortization

$370 k$310 k$203 k

Accounts Receivable

Inventories

Accounts Payable

$289 k$2.1 m($917 k)

Cash From Operating Activities

$264 k$107 k($16.7 m)

Capital Expenditures

($43 k)($412 k)($412 k)

Cash From Investing Activities

$131 k($412 k)($412 k)

Cash From Financing Activities

$40.3 m$164 k$175 k

Free Cash Flow

$307 k$519 k($16.3 m)

Aradigm Market Value History

Aradigm Company Life

You may also be interested in